دورية أكاديمية
Benfotiamine improves dystrophic pathology and exercise capacity in mdx mice by reducing inflammation and fibrosis.
| العنوان: | Benfotiamine improves dystrophic pathology and exercise capacity in mdx mice by reducing inflammation and fibrosis. |
|---|---|
| المؤلفون: | Coles CA; Murdoch Childrens Research Institute, The Royal Children's Hospital, 50 Flemington Road, Parkville, Victoria 3052, Australia.; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Flemington Road, Parkville, Victoria 3052, Australia., Woodman KG; Murdoch Childrens Research Institute, The Royal Children's Hospital, 50 Flemington Road, Parkville, Victoria 3052, Australia.; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Flemington Road, Parkville, Victoria 3052, Australia.; Department of Genetics, Yale Medical School, Yale University, 333 Cedar Street, New Haven, Connecticut 06520, USA., Gibbs EM; Department of Integrative Biology and Physiology, University of California, 612 Charles E Young Dr S, Los Angeles 90095, California, USA.; Center for Duchenne Muscular Dystrophy, University of California, 615 Charles E Young Dr S, Los Angeles 90095, California, USA., Crosbie RH; Department of Integrative Biology and Physiology, University of California, 612 Charles E Young Dr S, Los Angeles 90095, California, USA.; Center for Duchenne Muscular Dystrophy, University of California, 615 Charles E Young Dr S, Los Angeles 90095, California, USA.; Department of Neurology, David Geffen School of Medicine, University of California, 610 Charles E Young Dr S, Los Angeles, California 90095, USA., White JD; Murdoch Childrens Research Institute, The Royal Children's Hospital, 50 Flemington Road, Parkville, Victoria 3052, Australia.; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Flemington Road, Parkville, Victoria 3052, Australia.; Charles Sturt University, Office of the Deputy Vice Chancellor Research, Boorooma Street, Wagga Wagga, NSW 2678, Australia., Lamandé SR; Murdoch Childrens Research Institute, The Royal Children's Hospital, 50 Flemington Road, Parkville, Victoria 3052, Australia.; Department of Paediatrics, University of Melbourne, 50 Flemington Road, Parkville, Victoria 3052, Australia. |
| المصدر: | Human molecular genetics [Hum Mol Genet] 2024 Jul 22; Vol. 33 (15), pp. 1339-1355. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: IRL Press at Oxford University Press Country of Publication: England NLM ID: 9208958 Publication Model: Print Cited Medium: Internet ISSN: 1460-2083 (Electronic) Linking ISSN: 09646906 NLM ISO Abbreviation: Hum Mol Genet Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, England ; New York : IRL Press at Oxford University Press, c1992- |
| مواضيع طبية MeSH: | Mice, Inbred mdx* , Fibrosis*/drug therapy , Muscular Dystrophy, Duchenne*/drug therapy , Muscular Dystrophy, Duchenne*/genetics , Muscular Dystrophy, Duchenne*/pathology , Muscular Dystrophy, Duchenne*/physiopathology , Muscular Dystrophy, Duchenne*/metabolism , Inflammation*/drug therapy , Inflammation*/genetics , Inflammation*/pathology , Muscle, Skeletal*/drug effects , Muscle, Skeletal*/metabolism , Thiamine*/analogs & derivatives , Thiamine*/pharmacology, Animals ; Mice ; Male ; Physical Conditioning, Animal ; Disease Models, Animal |
| مستخلص: | Duchenne Muscular Dystrophy (DMD) is a progressive and fatal neuromuscular disease. Cycles of myofibre degeneration and regeneration are hallmarks of the disease where immune cells infiltrate to repair damaged skeletal muscle. Benfotiamine is a lipid soluble precursor to thiamine, shown clinically to reduce inflammation in diabetic related complications. We assessed whether benfotiamine administration could reduce inflammation related dystrophic pathology. Benfotiamine (10 mg/kg/day) was fed to male mdx mice (n = 7) for 15 weeks from 4 weeks of age. Treated mice had an increased growth weight (5-7 weeks) and myofibre size at treatment completion. Markers of dystrophic pathology (area of damaged necrotic tissue, central nuclei) were reduced in benfotiamine mdx quadriceps. Grip strength was increased and improved exercise capacity was found in mdx treated with benfotiamine for 12 weeks, before being placed into individual cages and allowed access to an exercise wheel for 3 weeks. Global gene expression profiling (RNAseq) in the gastrocnemius revealed benfotiamine regulated signalling pathways relevant to dystrophic pathology (Inflammatory Response, Myogenesis) and fibrotic gene markers (Col1a1, Col1a2, Col4a5, Col5a2, Col6a2, Col6a2, Col6a3, Lum) towards wildtype levels. In addition, we observed a reduction in gene expression of inflammatory gene markers in the quadriceps (Emr1, Cd163, Cd4, Cd8, Ifng). Overall, these data suggest that benfotiamine reduces dystrophic pathology by acting on inflammatory and fibrotic gene markers and signalling pathways. Given benfotiamine's excellent safety profile and current clinical use, it could be used in combination with glucocorticoids to treat DMD patients. (© The Author(s) 2024. Published by Oxford University Press.) |
| References: | Free Radic Biol Med. 2012 Jan 1;52(1):182-90. (PMID: 22067901) Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677) Neurology. 2018 Jun 12;90(24):e2146-e2154. (PMID: 29752304) Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404) J Neuromuscul Dis. 2021;8(s2):S343-S358. (PMID: 34180420) Naunyn Schmiedebergs Arch Pharmacol. 2008 Sep;378(3):283-91. (PMID: 18509620) Crit Care. 2024 Feb 6;28(1):41. (PMID: 38321529) Circ Heart Fail. 2010 Mar;3(2):294-305. (PMID: 20107192) J Pathol. 2003 Sep;201(1):149-59. (PMID: 12950028) Nature. 1992 Dec 10;360(6404):588-91. (PMID: 1461282) Ann Nutr Metab. 1991;35(5):292-6. (PMID: 1776825) Lancet Neurol. 2010 Jan;9(1):77-93. (PMID: 19945913) Nature. 1989 Mar 16;338(6212):259-62. (PMID: 2493582) Skelet Muscle. 2015 Jul 15;5:22. (PMID: 26180627) J Neuropathol Exp Neurol. 2010 Aug;69(8):771-6. (PMID: 20613637) Trials. 2020 Jul 06;21(1):614. (PMID: 32631405) Clin J Pain. 2013 Aug;29(8):717-24. (PMID: 23354008) Invest Ophthalmol Vis Sci. 2009 May;50(5):2276-82. (PMID: 19136698) J Matern Fetal Neonatal Med. 2022 Jun;35(11):2085-2090. (PMID: 32722956) Biochem Soc Trans. 2003 Dec;31(Pt 6):1423-5. (PMID: 14641079) PLoS One. 2011;6(6):e20609. (PMID: 21698237) Biochim Biophys Acta. 2007 Feb;1772(2):272-83. (PMID: 17034994) Eur Rev Med Pharmacol Sci. 2018 May;22(10):3261-3273. (PMID: 29863274) J Clin Invest. 2012 Jul;122(7):2590-600. (PMID: 22684102) Neuromuscul Disord. 2002 Oct;12 Suppl 1:S95-104. (PMID: 12206803) Muscle Nerve. 2001 Dec;24(12):1575-94. (PMID: 11745966) J Immunol. 2013 Oct 15;191(8):4337-47. (PMID: 24043885) Int J Clin Pharmacol Ther. 1996 Feb;34(2):47-50. (PMID: 8929745) Stem Cell Res. 2015 Jan;14(1):20-9. (PMID: 25460248) Eur J Clin Pharmacol. 1997;52(4):319-20. (PMID: 9248773) Cell. 1987 Dec 24;51(6):919-28. (PMID: 3319190) Sci Transl Med. 2015 Aug 5;7(299):299rv4. (PMID: 26246170) Pharmacol Res. 2010 Jun;61(6):482-8. (PMID: 20188835) Ann Neurol. 2012 Mar;71(3):304-13. (PMID: 22451200) Histochem Cell Biol. 2013 Jan;139(1):13-34. (PMID: 22926285) J Mol Cell Cardiol. 2010 Oct;49(4):625-38. (PMID: 20542491) Diabet Med. 2013 Oct;30(10):1204-8. (PMID: 23701274) J Neurol Sci. 1990 Dec;100(1-2):9-13. (PMID: 2089145) PLoS Curr. 2011 Nov 22;3:RRN1277. (PMID: 22183053) Nat Rev Neurol. 2019 Jul;15(7):373-386. (PMID: 31147635) Bioinformatics. 2016 Oct 1;32(19):3047-8. (PMID: 27312411) J Cell Biol. 1991 Jan;112(1):135-48. (PMID: 1986002) Immunity. 2017 Jul 18;47(1):15-31. (PMID: 28723547) F1000Res. 2017 Nov 14;6:2010. (PMID: 29333246) PLoS Curr. 2011 Dec 18;3:RRN1295. (PMID: 22457847) Sci Rep. 2019 Sep 10;9(1):12982. (PMID: 31506484) Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886) Rare Dis. 2015 Feb 23;3(1):e1010966. (PMID: 26481612) PLoS One. 2016 Mar 14;11(3):e0150818. (PMID: 26974331) Diabetes. 2006 Aug;55(8):2231-7. (PMID: 16873685) Biomed Res Int. 2014;2014:965631. (PMID: 24877152) Neurology. 1991 May;41(5):667-72. (PMID: 2027481) Arzneimittelforschung. 1998 May;48(5):461-8. (PMID: 9638312) Resuscitation. 2023 Dec;193:110018. (PMID: 37890576) Neurosci Lett. 2006 Feb 13;394(2):158-62. (PMID: 16260089) Hum Mol Genet. 2020 Feb 1;29(3):353-368. (PMID: 31696230) Exp Clin Endocrinol Diabetes. 2008 Nov;116(10):600-5. (PMID: 18473286) F1000Res. 2016 Jun 17;5:1408. (PMID: 27441086) Neurobiol Dis. 2008 Jul;31(1):1-19. (PMID: 18499465) Eur J Immunol. 2016 Feb;46(2):269-80. (PMID: 26626159) Diabetologia. 2008 Oct;51(10):1930-2. (PMID: 18663426) BMC Pharmacol. 2008 Jun 12;8:10. (PMID: 18549472) Diabetologia. 2006 Feb;49(2):405-20. (PMID: 16416271) Exp Cell Res. 2008 Apr 15;314(7):1553-65. (PMID: 18308302) J Neuropathol Exp Neurol. 2009 Jul;68(7):762-73. (PMID: 19535995) Hum Mol Genet. 2018 Nov 1;27(21):3734-3746. (PMID: 30085099) Acta Myol. 2012 Dec;31(3):184-95. (PMID: 23620650) Acta Myol. 2012 May;31(1):9-15. (PMID: 22655511) Free Radic Biol Med. 2010 May 15;48(10):1423-34. (PMID: 20219672) Gene Ther. 2014 Apr;21(4):413-21. (PMID: 24572787) N Engl J Med. 1989 Jun 15;320(24):1592-7. (PMID: 2657428) J Cell Biol. 2009 Aug 10;186(3):363-9. (PMID: 19651889) |
| معلومات مُعتمدة: | GNT1043837 National Health and Medical Research Council of Australia; 274143 Muscular Dystrophy Association USA; R01 AR048179 United States NH NIH HHS; Muscular Dystrophy Australia; Murdoch Children's Research Institute and the Victorian Government's Operational Infrastructure Support Program; F32 AR069469 United States AR NIAMS NIH HHS |
| فهرسة مساهمة: | Keywords: Duchenne; benfotiamine; inflammation; muscular dystrophy |
| المشرفين على المادة: | Y92OUS2H9B (benphothiamine) X66NSO3N35 (Thiamine) |
| تواريخ الأحداث: | Date Created: 20240506 Date Completed: 20240722 Latest Revision: 20240724 |
| رمز التحديث: | 20240725 |
| مُعرف محوري في PubMed: | PMC11262745 |
| DOI: | 10.1093/hmg/ddae066 |
| PMID: | 38710523 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2083 |
|---|---|
| DOI: | 10.1093/hmg/ddae066 |